Business Wire

Manipal Hospitals is the First in India to Adopt Masimo Patient SafetyNet™

Del

Masimo (NASDAQ: MASI) announced today that Manipal Hospitals is the first hospital in India to install Masimo Patient SafetyNet™, a remote monitoring and clinician notification system.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160225005616/en/

“With Patient SafetyNet, we are now able to monitor a certain set of patients 24x7,” said Gopal Devanahalli, Chief Operating Officer of Manipal Hospitals. “One of the key features of this system is its proprietary Signal Extraction Technology (SET®) that helps significantly reduce false alarms.”

“This is the technological advancement that we were awaiting,” said Dr. Nagendra Swamy SC, MD, Senior President, Manipal Health Enterprises, and Group Medical Director & Chairman, Quality Council, Manipal Health Enterprises. “The technology will notify the hospital team when there are signs of deterioration and allow our patients to be monitored even though the nurse is not physically in the room with them.”

Masimo Patient SafetyNet works in conjunction with Masimo bedside monitors which provide continuous and noninvasive monitoring of oxygen saturation (SpO2), pulse rate, respiration rate, and other parameters. When changes occur in the measured values, which may indicate deterioration in the patient’s condition, in addition to bedside alarms, Masimo Patient SafetyNet automatically sends wireless alerts directly to clinicians. Continuous patient surveillance with Masimo Patient SafetyNet has been shown to reduce the need for rescue events and intensive care unit transfers in hospitals and, as a result, can reduce costs related to these events.1,2

“Manipal Hospitals treats close to 2 million patients annually and needed a monitoring system that they could trust would work in challenging patient populations,” said Joe Kiani, Founder and CEO of Masimo. “We are excited to see this shift internationally with more and more hospitals worldwide recognizing the importance of integrating remote monitoring systems as a part of their patient safety initiatives.”

@MasimoInnovates | #Masimo

1 Taenzer A.H., Pyke J.B., McGrath S.P., Blike G.T. Anesthesiology. 2010 Feb;112(2):282-7.

2 Taenzer A, Blike G, McGrath S, Pyke J, Herrick M, Renaud C, Morgan J. “Postoperative Monitoring - The Dartmouth Experience.” Anesthesia Patient Safety Foundation Newsletter Spring-Summer 2012. Available online.

About Manipal Hospitals

As a pioneer in healthcare, Manipal Hospitals is among the largest hospital networks in India, serving over 2 million patients annually. Its focus is to develop an affordable tertiary care multispecialty healthcare framework through its entire multispecialty delivery spectrum and further extend it to homecare. With its flagship quaternary care facility located in Bengaluru, India, 8 tertiary care, 7 secondary care and 2 primary care clinics spread across India and abroad, today Manipal Hospitals successfully operates and manages 5,200+ beds. Manipal Hospitals provides comprehensive curative and preventive care for a multitude of patients from across the globe. Manipal Hospitals is the first in India to be awarded accreditation by the AAHRPP for ethical standards in clinical research activities. It is also NABL, NABH and ISO certified. Manipal Hospitals is also the most respected hospital company in India and the most patient recommended hospital in India by consumer survey.

About Masimo

Masimo (NASDAQ: MASI) is a global leader in innovative noninvasive monitoring technologies. Our mission is to improve patient outcomes and reduce the cost of care by taking noninvasive monitoring to new sites and applications. In 1995, the company debuted Masimo SET® Measure-through Motion and Low Perfusion™ pulse oximetry, which has been shown in multiple studies to significantly reduce false alarms and accurately monitor for true alarms. The benefits of Masimo SET® have been proven in more than 100 independent and objective studies and it is estimated to be used on more than 100 million patients in leading hospitals and other healthcare settings around the world. In 2005, Masimo introduced rainbow® Pulse CO-Oximetry technology, allowing noninvasive and continuous monitoring of blood constituents that previously could only be measured invasively, including total hemoglobin (SpHb®), oxygen content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), and more recently, Pleth Variability Index (PVI®) and Oxygen Reserve Index (ORI™), in addition to SpO2, pulse rate, and perfusion index (PI). In 2014, Masimo introduced Root®, an intuitive open architecture patient monitoring and connectivity platform designed to speed the pace of innovation and reduce the cost of care. Masimo is also taking an active leadership role in mHealth with products such as the Radius-7™ wearable patient monitor and the MightySat™ fingertip pulse oximeter. Additional information about Masimo and its products may be found at www.masimo.com.

Forward-Looking Statements

This press release includes forward-looking statements as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, in connection with the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, among others, statements regarding the potential effectiveness of Masimo Patient SafetyNet™. These forward-looking statements are based on current expectations about future events affecting us and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond our control and could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements as a result of various risk factors, including, but not limited to: risks related to our assumptions regarding the repeatability of clinical results or studies; risks related to our belief that Masimo's unique noninvasive measurement technologies and monitoring system solutions, including Masimo Patient SafetyNet, contribute to positive clinical outcomes and patient safety; risks related to our belief that Masimo noninvasive medical breakthroughs provide cost-effective solutions with comparable accuracy and unique advantages, including: immediate and continuous results that enable earlier treatment without causing invasive trauma in all patients and in every clinical situation, including the dental setting; as well as other factors discussed in the "Risk Factors" section of our most recent reports filed with the Securities and Exchange Commission ("SEC"), which may be obtained for free at the SEC's website at www.sec.gov. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. We do not undertake any obligation to update, amend or clarify these statements or the "Risk Factors" contained in our most recent reports filed with the SEC, whether as a result of new information, future events or otherwise, except as may be required under the applicable securities laws.

Contact information

Masimo
Media:
Irene Paigah, +1-858-859-7001
irenep@masimo.com
or
Manipal Hospitals
Media:
Anjana Chandran, +91-988-627-8400
anjana.chandran@manipalhospitals.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

SmartStream and Credit Suisse Expand their Agreement from the Processing of Invoices and Reconciliations to Now Include Listed Derivatives Brokerage Fees18.10.2017 12:00Pressemelding

SmartStream Technologies, the financial Transaction Lifecycle Management (TLM®) solutions provider, today announced that its original agreement with Credit Suisse was recently expanded to include the processing of Listed Derivatives Brokerage fees which began in February of this year. This expansion in SmartStream’s partnership with Credit Suisse complements its existing managed service solution for the processing of invoices and reconciliations within Credit Suisse’s OTC Fixed Income Derivatives, US Listed Equity Options and Cash Equities businesses across brokerage, clearing and exchange fees operations, which began in June of 2016. The managed service enables the bank to advance the operational efficiencies created through the use of the utility-based solutions offered by SmartStream, utilizing their proprietary execution fees and expense management software. By centralizing the ent

Biogen Confirms Commitment to Tackle Multiple Sclerosis Through Comprehensive Approach18.10.2017 11:30Pressemelding

Biogen (NASDAQ: BIIB) confirms its comprehensive approach to tackle multiple sclerosis (MS) at the seventh Joint Meeting of the European Committee for Treatment and Research in MS and Americas Committee for Treatment and Research in MS (ECTRIMS-ACTRIMS; 25 – 28 October). “With more than 25 years of scientific leadership in MS, Biogen’s commitment is unwavering,” said Michael Ehlers, executive vice president, Research & Development at Biogen. “Our expertise puts Biogen in a unique position with a comprehensive approach including active research and clinical development on how to repair the damage to the central nervous system from relapsing forms of MS, a portfolio of new drug candidates that we are advancing to the clinic, our collaboration to identify a digital biomarker, our focus to advance understanding of the disease through global data collection with MS PATHS, active pursuit

Scientist.com Collaborates With UKCRC Tissue Directory and Coordination Centre to Ensure Quality of Human Biosample Acquisition Globally18.10.2017 11:01Pressemelding

Scientist.com, the world’s leading marketplace for outsourced scientific services, today announced that it is entering into a collaboration with the UKCRC Tissue Directory and Coordination Centre (UKCRC TDCC) to support the work of biobanks throughout the United Kingdom. The partnership will enable drug R&D to move forward more quickly by making large collections of prescreened human biological samples available for scientific research. Through the new COMPLI™ feature, Scientist.com provides a simple, efficient and effective way of increasing the visibility and accessibility of biobanks’ human biological samples collections, which support new medical research. COMPLI™ introduces a common, comprehensive process and supply agreement supporting access to human biosamples. The goal is to enable biobanks to more easily connect with researchers in the pharmaceutical and biotech indust

Assurant to Acquire the Warranty Group in Transaction Valued at $2.5 Billion18.10.2017 10:30Pressemelding

Assurant, Inc. (NYSE:AIZ), a premier global provider of risk management solutions, and The Warranty Group, a leading global provider of protection plans and related programs, and a portfolio company of TPG Capital, today announced that they have entered into a definitive agreement to combine operations, with Assurant shareholders retaining majority ownership of the combined company. The transaction is valued at approximately $2.5 billion and is expected to close in the first half of 2018, subject to shareholder and regulatory approvals, and other customary closing conditions. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171018005269/en/ The transaction will significantly advance Assurant’s strategy in the global lifestyle market with an attractive product and client portfolio, diversified growth profile and a deeper glob

Boost the Connectivity and Memory on Your Phone with FuZion18.10.2017 09:47Pressemelding

IDEMIA (formerly known as OT-Morpho), the global leader in trusted identities for an increasingly digital world, today announces the solution for a problem everyone encounters: the choice between connectivity and memory for one’s smartphone. With FuZion, a fantastic device combining the technologies of a SIM card with a microSD card, users will never have to make this choice again. Nowadays, most people need to have two SIM cards, one for personal use and the other for a professional one. At the same time, people require their smartphone to have a lot of memory. That is why today, more and more smartphones have a dual SIM tray, with a hybrid slot for two SIM cards or for one SIM card and a microSD card. With FuZion, no compromises: users can simultaneously have two SIM cards and a microSD card in their phone. FuZion is available for more than 50 smartphone models from

Capgemini Gives Technology a Human Touch, with a New Brand Identity Designed by BrandPie.18.10.2017 08:30Pressemelding

Capgemini, one of the world’s leading global technology and consulting firms, yesterday launched its new brand identity, designed by strategic brand consultancy BrandPie. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171018005101/en/ Capgemini's new brand identity, designed by BrandPie BrandPie worked in close collaboration with Capgemini’s leadership team over 15 months to create a dynamic digital-first brand identity and wordmark, inspired by the handwriting of Serge Kampf, Capgemini’s founder. Meanwhile, its iconic spade emblem has been redrawn to reflect the world the business is now in. Coinciding with the Group’s 50th anniversary, this is the first overhaul of Capgemini’s brand identity since 2004, and has been crafted to ensure that it remains ahead of its peers in its

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom